Clinical Trial Update: Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on the antipsychotic effects of JOBELYN, derived from Sorghum bicolor, in treating schizophrenia, conducted in Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Jobelyn

Snippet

Sponsor: Federal Neuro-Psychiatric Hospital, Yaba | Conditions: Schizophrenia and Disorders With Psychotic Features | Phase 1, Phase 2 | Status: UNKNOWN